Clinical Trials Browser

Metastatic Hormone-sensitive Prostate Cancer × Androgen Antagonists × Clear all

NCT00309985 2025-12-11

CHAARTED

Phase 3 Completed

790 enrolled 11 charts

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Phase 3 Completed

1,306 enrolled 25 charts 2 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT06498921 2024-10-24

BELBEQA

Metastatic Hormone-sensitive Prostate Cancer